TSLA
Tesla
-- 463.020 NVDA
NVIDIA
-- 132.000 PLTR
Palantir
-- 75.750 MSTR
MicroStrategy
-- 408.500 AVGO
Broadcom
-- 250.000 
NEWS
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
Monday, 16th December at 8:00 am
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)
One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS
Mec-V antitumor activity observed across 9 different mKRAS variants
Strong association of AXL expression by mKRAS NSCLC confirmed
Monday, 16th December at 8:00 am
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)
One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS
Mec-V antitumor activity observed across 9 different mKRAS variants
Strong association of AXL expression by mKRAS NSCLC confirmed
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment